154 related articles for article (PubMed ID: 37315342)
1. Halogenated class of oximes as a new class of monoamine oxidase-B inhibitors for the treatment of Parkinson's disease: Synthesis, biochemistry, and molecular dynamics study.
Thomas Parambi DG; Oh JM; Kumar S; Sudevan ST; Hendawy OM; Abdelgawad MA; Musa A; Al-Sanea MM; Ahmad I; Patel H; Kim H; Mathew B
Comput Biol Chem; 2023 Aug; 105():107899. PubMed ID: 37315342
[TBL] [Abstract][Full Text] [Related]
2. Introduction of benzyloxy pharmacophore into aryl/heteroaryl chalcone motifs as a new class of monoamine oxidase B inhibitors.
Sudevan ST; Oh JM; Abdelgawad MA; Abourehab MAS; Rangarajan TM; Kumar S; Ahmad I; Patel H; Kim H; Mathew B
Sci Rep; 2022 Dec; 12(1):22404. PubMed ID: 36575270
[TBL] [Abstract][Full Text] [Related]
3. The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor.
Zarmouh NO; Eyunni SK; Soliman KF
BMC Complement Altern Med; 2017 Jan; 17(1):34. PubMed ID: 28069007
[TBL] [Abstract][Full Text] [Related]
4. Ethyl Acetohydroxamate Incorporated Chalcones: Unveiling a Novel Class of Chalcones for Multitarget Monoamine Oxidase-B Inhibitors Against Alzheimer's Disease.
Reeta ; Baek SC; Lee JP; Rangarajan TM; Ayushee ; Singh RP; Singh M; Mangiatordi GF; Nicolotti O; Kim H; Mathew B
CNS Neurol Disord Drug Targets; 2019; 18(8):643-654. PubMed ID: 31550216
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 3,4-dichloro-N-(1H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action.
Elkamhawy A; Kim HJ; Elsherbeny MH; Paik S; Park JH; Gotina L; Abdellattif MH; Gouda NA; Cho J; Lee K; Nim Pae A; Park KD; Roh EJ
Bioorg Chem; 2021 Nov; 116():105352. PubMed ID: 34562673
[TBL] [Abstract][Full Text] [Related]
6. Calycosin and 8-O-methylretusin isolated from Maackia amurensis as potent and selective reversible inhibitors of human monoamine oxidase-B.
Oh JM; Jang HJ; Kim WJ; Kang MG; Baek SC; Lee JP; Park D; Oh SR; Kim H
Int J Biol Macromol; 2020 May; 151():441-448. PubMed ID: 32087226
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies.
Elkamhawy A; Paik S; Park JH; Kim HJ; Hassan AHE; Lee K; Park KD; Roh EJ
Bioorg Chem; 2021 Oct; 115():105233. PubMed ID: 34390968
[TBL] [Abstract][Full Text] [Related]
8. Potent and selective inhibition of human monoamine oxidase-B by 4-dimethylaminochalcone and selected chalcone derivatives.
Oh JM; Kang MG; Hong A; Park JE; Kim SH; Lee JP; Baek SC; Park D; Nam SJ; Cho ML; Kim H
Int J Biol Macromol; 2019 Sep; 137():426-432. PubMed ID: 31271801
[TBL] [Abstract][Full Text] [Related]
9. Medicarpin and Homopterocarpin Isolated from
Oh JM; Jang HJ; Kang MG; Mun SK; Park D; Hong SJ; Kim MH; Kim SY; Yee ST; Kim H
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615451
[TBL] [Abstract][Full Text] [Related]
10. Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
Baek SC; Kang MG; Park JE; Lee JP; Lee H; Ryu HW; Park CM; Park D; Cho ML; Oh SR; Kim H
Bioorg Med Chem Lett; 2019 Mar; 29(6):839-843. PubMed ID: 30686752
[TBL] [Abstract][Full Text] [Related]
11. Development of methylthiosemicarbazones as new reversible monoamine oxidase-B inhibitors for the treatment of Parkinson's disease.
Mathew GE; Oh JM; Mohan K; Tengli A; Mathew B; Kim H
J Biomol Struct Dyn; 2021 Aug; 39(13):4786-4794. PubMed ID: 32588753
[TBL] [Abstract][Full Text] [Related]
12. Potent and Selective Monoamine Oxidase-B Inhibitory Activity: Fluoro- vs. Trifluoromethyl-4-hydroxylated Chalcone Derivatives.
Mathew B; Mathew GE; Uçar G; Baysal I; Suresh J; Mathew S; Haridas A; Jayaprakash V
Chem Biodivers; 2016 Aug; 13(8):1046-52. PubMed ID: 27402375
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel 3,4-dihydrocoumarins as potent and selective monoamine oxidase-B inhibitors with the neuroprotection against Parkinson's disease.
Liu L; Chen Y; Zeng RF; Liu Y; Xie SS; Lan JS; Ding Y; Yang YT; Yang J; Zhang T
Bioorg Chem; 2021 Apr; 109():104685. PubMed ID: 33640631
[TBL] [Abstract][Full Text] [Related]
14. Development of Halogenated Pyrazolines as Selective Monoamine Oxidase-B Inhibitors: Deciphering via Molecular Dynamics Approach.
Nair AS; Oh JM; Koyiparambath VP; Kumar S; Sudevan ST; Soremekun O; Soliman ME; Khames A; Abdelgawad MA; Pappachen LK; Mathew B; Kim H
Molecules; 2021 May; 26(11):. PubMed ID: 34071665
[TBL] [Abstract][Full Text] [Related]
15. Exploration of chlorinated thienyl chalcones: A new class of monoamine oxidase-B inhibitors.
Mathew B; Haridas A; Uçar G; Baysal I; Adeniyi AA; Soliman ME; Joy M; Mathew GE; Lakshmanan B; Jayaprakash V
Int J Biol Macromol; 2016 Oct; 91():680-95. PubMed ID: 27262516
[TBL] [Abstract][Full Text] [Related]
16. Exploration of Umbelliferone Based Derivatives as Potent MAO Inhibitors: Dry vs. Wet Lab Evaluation.
Dhiman P; Malik N; Khatkar A
Curr Top Med Chem; 2018; 18(21):1857-1871. PubMed ID: 30430943
[TBL] [Abstract][Full Text] [Related]
17. Identification of Indole-Based Chalcones: Discovery of a Potent, Selective, and Reversible Class of MAO-B Inhibitors.
Sasidharan R; Manju SL; Uçar G; Baysal I; Mathew B
Arch Pharm (Weinheim); 2016 Aug; 349(8):627-37. PubMed ID: 27373997
[TBL] [Abstract][Full Text] [Related]
18. Biphenylpiperazine Based MAO Inhibitors: Synthesis, Biological Evaluation, Reversibility and Molecular Modeling Studies.
El-Halaby LO; El-Husseiny WM; El-Messery SM; Goda FE
Bioorg Chem; 2021 Oct; 115():105216. PubMed ID: 34352710
[TBL] [Abstract][Full Text] [Related]
19. Monoamine Oxidase Inhibitory Activity: Methyl- versus Chlorochalcone Derivatives.
Mathew B; Uçar G; Mathew GE; Mathew S; Kalatharakkal Purapurath P; Moolayil F; Mohan S; Varghese Gupta S
ChemMedChem; 2016 Dec; 11(24):2649-2655. PubMed ID: 27902880
[TBL] [Abstract][Full Text] [Related]
20. Assembling a Cinnamyl Pharmacophore in the C3-Position of Substituted Isatins via Microwave-Assisted Synthesis: Development of a New Class of Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease.
Manoharan A; Oh JM; Benny F; Kumar S; Abdelgawad MA; Ghoneim MM; Shaker ME; El-Sherbiny M; Almohaimeed HM; Gahtori P; Kim H; Mathew B
Molecules; 2023 Aug; 28(16):. PubMed ID: 37630420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
